DISCOVER

VASCEPA®

EXPERIENCED

in lipid science

INVESTOR

relations

VASCEPA®

LIPID SCIENCE

investor relations

welcome


therapeutics to improve cardiovascular health

Amarin Corporation plc is a rapidly growing, innovative pharmaceutical company focused on developing and commercializing therapeutics to cost-effectively improve cardiovascular health. Amarin’s lead product, VASCEPA® (icosapent ethyl) capsules, is available by prescription in the United States and an increasing number of other countries.

The History of VASCEPA®


Development of VASCEPA® leveraged Amarin’s extensive experience in the therapeutic benefits of polyunsaturated fatty acids and lipid science. The development of VASCEPA® challenged previously established understandings of the treatment of complex disease states and created an important new drug with the potential to significantly improve patient care for millions of patients. The use of VASCEPA® is supported by over 200 issued patents worldwide. VASCEPA® was designated by FDA as a new chemical entity in recognition of the drug’s novel single active ingredient. Similar designations have also been granted to VASCEPA®’s active ingredient in other jurisdictions internationally.

MORE

recent news


Apr 12, 2021

Amarin Announces CEO Succession Plan MORE

Apr 6, 2021

Amarin Commences Commercial Initiatives for VAZKEPA in European Union Following Recent Regulatory Approval for Cardiovascular Risk Reduction Indication MORE

Stock Information

Symbol:
AMRN (NASDAQ)
Quote:
$5.08
Change:
-0.76
Date:
4:00 PM on Apr 13, 2021
(latest end of day stock price)
Investor
Relations
Executive
Team
Career
Opportunities
FAQs
Contact
Amarin

Amarin
Corporation

therapeutics to improve
cardiovascular health.

Join Our Mailing List

You may automatically receive Amarin Corporation plc financial information by email.


Click To Subscribe